Compare Dyne Therapeutics Inc. Common Stock (DYN) vs LifeStance Health Group Inc. Common Stock (LFST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs LifeStance Health Group Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while LifeStance Health Group Inc. Common Stock trades at $12.7 (market cap $4.69B). The key difference: LifeStance Health Group Inc. Common Stock is the larger of the two by market cap, and LifeStance Health Group Inc. Common Stock is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and LifeStance Health Group Inc. Common Stock for 6 Days on average.
| DYN | LFST | |
|---|---|---|
Market Cap | $2.81B | $4.69B |
Volume | 2,195,902 | 1,858,220 |
Sector | Health | Health |
52-Week High | $26.78 | $13.38 |
52-Week Low | $14.60 | $4.81 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.13B | $4.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
LifeStance Health Group (LFST) trades at $12.32, down 1.28% today, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.06 exceeding the $0.03 forecast. Revenue growth accelerated from $1.42B in 2025 to $1.6B in 2026, while net income improved significantly from $9.66M to $51M.
Wall Street maintains strong bullish sentiment with 82% buy ratings and a $14.14 consensus price target representing 15% upside. However, elevated valuation multiples (P/E 94.8) and overbought technical conditions near 52-week highs warrant caution. The mental healthcare provider benefits from industry tailwinds but faces execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About LifeStance Health Group Inc. Common Stock
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →
